Canada to Unveil Response to US Tariffs Next Week, Carney Says
By and Brian Platt
Save
Prime Minister Mark Carney says Canada will fight back against President Donald Trump's trade war and his tariffs on the auto sector, but he did not outline any new retaliatory measures against the US on Thursday.
The Canadian government will respond based on what the US administration does on April 2, the day Trump has promised to unveil another round of import taxes, Carney told reporters in Ottawa after holding an urgent meeting with a cabinet group that's focused on Canada-US relations.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
In the news today: Carney making defence announcement in Toronto
Here is a roundup of stories from The Canadian Press designed to bring you up to speed... Carney making defence announcement in Toronto Prime Minister Mark Carney's office says he will be in Toronto today to make an announcement related to "defence and security priorities." The announcement is slated for 10 a.m., after which he is set to tour a local military facility before holding a news conference at 1 p.m. Defence ministers from NATO countries met in Brussels last week to discuss raising the member spending target on defence to as much as five per cent of GDP. Canada has never met NATO's existing spending target of two per cent since it was established in 2006, and the topic will loom large when NATO leaders meet later this month in the Netherlands. Carney promised during the recent election campaign to move up Canada's deadline for meeting the two per cent threshold from 2032 to 2030 or sooner, but hasn't yet revealed a plan for meeting that figure. Here's what else we're watching... B.C. wildfires merge, spurring evacuation order The BC Wildfire Service says the Pocket Knife Creek wildfire in the province's northeast has merged with another blaze, increasing its size "substantially." It says the fire is now more than 610 square kilometres in size and is considered an out-of-control wildfire of note. The Peace River Regional District says the fire poses an "immediate danger to life safety" and issued an evacuation order Sunday for the area approximately nine kilometres west of the Buckinghorse River, and around the Redfern Trail down toward Redfern Lake. The regional district issued earlier evacuation orders due to the Kiskatinaw River wildfire, another wildfire of note near the B. C-Alberta border that's about 130 square kilometres in size. The service says the third wildfire of note is the Summit Lake wildfire, and is also expected to keep growing due to winds and warm weather, and is now about 106 square kilometres. Six infants born with congenital measles in Ontario Ontario's chief medical officer of health says six infants have been born with congenital measles since an outbreak began last fall, adding they were infected in the womb through mothers who were not vaccinated. Dr. Kieran Moore says these infants recovered, but their infections could have been prevented if their mothers had been vaccinated and protected from contracting measles. Congenital measles can result in severe complications, including inflammation of the brain and death. On Thursday, Moore announced an infant born prematurely and infected with measles died in southwestern Ontario. He says the infant also faced other serious medical complications unrelated to the virus. B.C. pediatric closure spurs fear of ripple effect Dr. Jeff Eppler, an emergency room physician at Kelowna General Hospital, is getting ready for a hectic summer. He's not only thinking about the typical seasonal spike — but the ripple effects of the closure of the hospital's dedicated pediatric ward from May 26 to July 4 due to what Interior Health called "limited physician availability." And Eppler predicted the resource drain would extend outside the hospital, to ambulance services, as Kelowna General is forced to send other children to other hospitals, in Vernon, Penticton, or potentially even the Kootenays more than 300 kilometres away. Typically, it's the other way around. The closure of Kelowna's pediatric ward is part of ongoing hospital staffing shortages that have caused rolling closures of emergency rooms across the province. Service disruptions at the pediatric ward and concerns about the state of care at Kelowna General are also not new. But the abrupt nature of the pediatric closure last week, and a recent warning from doctors about maternity care is putting one of the province's biggest regional hospitals in the spotlight. A year of banning cellphones in school classrooms Sixteen-year-old Roha Akram was skeptical when teachers in Calgary announced a cellphone ban during the first assembly of the school year. She said the ban has been good for some students, who just need a reminder to focus in class, particularly when teachers are speaking. But some have struggled. As the school year wraps up this month, education ministries across Canada say there have been overall positive results from banning cellphones. Last fall, most provinces introduced policies to limit cellphone use in schools, similar to jurisdictions in other countries. Ontario's education ministry said parents and teachers find the ban has created a better learning environment. This report by The Canadian Press was first published June 9, 2025. The Canadian Press
Yahoo
36 minutes ago
- Yahoo
Bladder Cancer Drug Market Forecast and Analysis Report 2025: Focus on US, France, Germany, Italy, Spain, UK, Japan, and China - Epidemiology, Pipeline Therapies, 10 Year Forecasts
Explore the comprehensive "Bladder Cancer: Eight-Market Drug Forecast and Market Analysis" report, covering the 8 major markets (US, France, Germany, Italy, Spain, UK, Japan, China). Gain insights into disease epidemiology, 10-year patient-based forecasts, and market trends, as well as late-stage pipeline therapies set to drive market growth. Dublin, June 09, 2025 (GLOBE NEWSWIRE) -- The "Bladder Cancer: Eight-Market Drug Forecast and Market Analysis" report has been added to Highlights Report deliverables include a Pdf report and Excel-based forecast model Forecasts includes the 8MM Forecasts covers from 2021-2031 The analyst valued the bladder cancer market in the 8MM at $2.39 billion and expects the market to increase to $2.89 billion by 2031 Incyte, GSK and CTI BioPharma are expected to take market-leading position in 2031 A moderate level of unmet need will remain for most bladder cancer patient populations during the forecast period The late-stage pipeline in bladder cancer is robust and is likely to provide significant clinical benefit to many bladder cancer patient populations, with fierce competition expected This report includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the 8MM for marketed and late-stage pipeline therapies, with a launch date assessment by market for bladder cancer. These sales forecasts leverage data on pharmaceutical sales and drug availability from the analyst's World Markets Healthcare (WMH) and POLI Price Intelligence being a rare blood cancer, MF is a blockbuster market and is expected to grow from sales of $2.39 billion in 2021 to $2.89 billion in 2031, at a compound annual growth rate (CAGR) of 1.9%. Peak-year sales are set to be reached in 2027, driven by the approvals of several promising late-stage pipeline agents and the continued clinical dominance of Jakafi/Jakavi (ruxolitinib). In 2028, Jakafi/Jakavi is set to come off-patent in the US, which will greatly decrease its total market sales. However, the loss of total market sales will be somewhat recuperated in 2028 and beyond by the additional growth in market value of other pipeline Janus kinase (JAK) inhibitors and targeted therapies, with sales of these agents being driven by ameliorating critical unmet needs within the MF treatment markets across the 8MM will experience growth driven by common drivers: Approvals of late-stage pipeline agents, including novel JAK inhibitors and targeted therapies, which will partially meet critical unmet clinical needs Decreased reliance on generic immunomodulatory agents, androgens, and erythropoietin-stimulating agents Increased utilization of novel combination regimens with premium-priced agents Common barriers to market growth experienced across the 8MM primarily include a series of patent expiries: Patent expiry of Jakafi/Jakavi Patent expiry of Vonjo (pacritinib) Patent expiry of Inrebic (fedratinib) Key Highlights This report covers the eight major markets (8MM: US, France, Germany, Italy, Spain, the UK, Japan and China). The report provides an overview of the current treatment options, pipeline products in development, as well as current and future R&D trends. Key topics covered include a strategic competitive assessment of current and future drugs, unmet needs, KOL insights, and implications for the severe asthma market. The base year of the sales forecast model is 2023, and the forecast period is 2023-2033. Scope Overview of bladder cancer, including epidemiology, symptoms, diagnosis, and disease management. Annualized bladder cancer therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2023 to 2033. Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the bladder cancer therapeutics market. Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for bladder cancer treatment. The most promising candidates in Phase III and Phase IIb development are profiled. Analysis of the current and future market competition in the global bladder cancer therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications Reasons to Buy Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Develop business strategies by understanding the trends shaping and driving the global bladder cancer therapeutics market. Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global bladder cancer therapeutics market in the future. Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships Key Topics Covered: Abbreviations Related Reports Executive Summary Disease Overview Overview of Bladder Cancer Bladder Cancer Market Strength, Weakness, Opportunity, and Threat Analysis Epidemiology Diagnosed Incident Cases Both Sexes Age-Specific Diagnosed Incident Cases Sex-Specific Diagnosed Incident Cases Diagnosed Incident Cases by Type, Sex, Age Diagnosed Incident Cases by Stage at Diagnosis Diagnosed Incident Cases by Tumor Stage at Diagnosis Diagnosed Incident Cases of Stage Ta Bladder Cancer by Grade Diagnosed Incident Cases of Stage of Bladder Cancer by Broad Classification Diagnosed Incident Cases of Stage of NMIBC by Risk Group Diagnosed Incident Cases of Bladder Cancer by Mutations and Biomarkers Five-Year Diagnosed Prevalent Cases of Bladder Cancer Five-Year Diagnosed Prevalent Cases of Bladder Cancer by Tumor Stage Five-Year Diagnosed Prevalent Cases of Bladder Cancer by Broad Classification Five-Year Diagnosed Prevalent Cases of Bladder Cancer by Relapse or Recurrence Five-Year Diagnosed Prevalent Cases of Bladder Cancer by Treatment Disease Management Treatment Guidelines Treatment Paradigm - First-Line Therapy in Non-Muscle Invasive Bladder Cancer Treatment Paradigm - First-Line Therapy in Muscle Invasive Bladder Cancer Treatment Paradigm - Locally Advanced/Metastatic Bladder Cancer KOL Insight on the Bladder Cancer Treatment Algorithm Unmet Needs and Opportunities Unmet Needs in Bladder Cancer Competitive Landscape Assessment Pipeline Drugs Overview Competitive Landscape Methodology Competitive Assessment - Intravesical Delivered Therapies for NMIBC Competitive Assessment - Gene Therapies for NMIBC Competitive Assessment - Antibody-Drug Conjugates Market Outlook Bladder Cancer Market Forecast Bladder Cancer Market Forecast by Class Bladder Cancer Market Drivers and Barriers Appendix Primary Research: KOL Information Sources Used and Not Used to Forecast Diagnosed Incident Cases Sources Used to Forecast Diagnosed Incident Cases by Stage at Diagnosis Sources Used to Forecast Diagnosed Incident Cases by Tumor Stage at Diagnosis Sources Used to Forecast Diagnosed Incident Cases of Stage Ta Bladder Cancer by Grade Sources Used to Forecast Diagnosed Incident and Five-Year Diagnosed Prevalent Cases by Broad Classification Sources Used to Forecast Diagnosed Incident Cases of NMIBC by Risk Group Sources Used to Forecast Diagnosed Incident Cases by Mutations and Biomarkers Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases by Relapse or Recurrence Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases by Treatment Sources and Methodology Epidemiological Forecast Insight Strengths and Limitations A selection of companies mentioned in this report includes, but is not limited to: AstraZeneca Merck Bristol-Myers Squibb Gilead Sciences LLC Roche Pfizer Immunomedics Inc Astellas Pharma Co Ltd Johnson & Johnson Daiichi Sankyo Co Ltd Ferring Pharmaceuticals Ltd ImmunityBio Inc BeiGene Ltd Bicycle Therapeutics Inc CG Oncology Inc Shanghai Miracogen Inc Fidia farmaceutici SpA Therlase Inc enGene Holdings Inc UroGen Pharma Inc For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
36 minutes ago
- Yahoo
Mining Industry Quarterly Review, Q4 2024 & Full Year - Top 18 Mining Companies Invest $69.1B in 2024; Forecasted Increase for 2025
"Mining Quarterly Review - Q4 2024 & Full Year" analyzes global mining trends, covering commodities, production, and capital expenditure. Indonesia achieved record coal outputs while boosting its nickel industry. Glencore led in coal production growth, driven by key acquisitions. Top miners spent $69.1B in 2024, with a 2025 rise forecasted. Key regions include Canada, Australia, South Africa, and the US. Dublin, June 09, 2025 (GLOBE NEWSWIRE) -- The "Mining Quarterly Review - Q4 2024 & Full Year" report has been added to offering. The report contains an overview of the key commodities in the mining industry including coal, iron ore, copper, gold, nickel, lead, zinc, uranium and lithium. It provides detailed information on prices, production by country, production by company, development projects update, capital expenditure, and demand "Mining Quarterly Review - Q4 2024 & Full Year" provides a comprehensive coverage on the global mining industry. It provides commodity trends covering price trends, production, capital expenditure of leading miners, development projects momentum, development projects by commodity, country, company and stage. The report also includes a demand drivers section providing information on factors that are affecting the global mining industry. It further provides updates on emissions, safety in mining, regulatory, developments in mining for Q4 2024 & Full Year, European Union's industrial production, US' industrial production, China's industrial production growth rate, China's Manufacturing PMI .While maintaining strong coal production, Indonesia is also navigating the global energy transition. This involves balancing coal output with the development of its nickel industry, crucial for EV batteries. Indonesia surpassed its 2024 coal production targets, reaching record highs to 836Mt, driven by both domestic and international demand. In Q4 2024, Glencore recorded the highest coal production growth, significantly outpacing its competitors. Yanzhou, Coal India and China Shenhua Energy also registered growth, though at a much smaller scale. Glencore experienced a significant increase in metallurgical coal production, rising by 18.9% compared to the same period in 2023. This substantial growth was primarily attributable to the acquisition of Canadian steelmaking operations, Elk Valley Resources (EVR), in July 2024. After 0.82% of projects in the development stages advanced in Q3 2024, the development projects momentum improved to 1.37% in Q4 2024. Some 37 projects advanced during this quarter, of which 16 were in Canada, Australia, South Africa and the US, 2024, the world's top 18 mining companies collectively invested over $69.1B in capital expenditures. Companies' projections for 2025 indicate a 5.1% increase to $72.7B for the same 18 to Buy To gain an understanding of the quarterly changes in the global mining industry, relevant driving factors To understand historical and forecast trends on key commodities To identify key players in the global mining industry To identify major development projects momentum by region To identify the trend in capital expenditure spent by leading miners To understand the factors influencing demand drivers of key commodities Key Topics Covered: Overview Macroeconomic trends Commodity trends Coal Iron ore Copper Gold Nickel Lead Zinc Uranium Lithium Development projects update Capital expenditure Demand drivers Appendix For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
